Antiparkinson Agents (Antiparkinsonian Agents)

Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.

Also Known As:

Networked: 93 relevant articles (7 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Stuart, Bruce: 3 articles (03/2014 - 08/2010)
2.	Millan, Mark J: 3 articles (02/2011 - 11/2002)
3.	Beardsley, Robert: 2 articles (03/2014 - 10/2013)
4.	Shulman, Lisa M: 2 articles (03/2014 - 10/2013)
5.	Palumbo, Francis B: 2 articles (03/2014 - 10/2013)
6.	Wei, Yu-Jung: 2 articles (03/2014 - 10/2013)
7.	Simoni-Wastila, Linda: 2 articles (03/2014 - 10/2013)
8.	Tasca, Carla I: 2 articles (06/2013 - 01/2011)
9.	Castro, Adalberto A: 2 articles (06/2013 - 01/2011)
10.	Matheus, Filipe C: 2 articles (06/2013 - 01/2011)

Related Diseases

1.	Dyskinesias (Dyskinesia) 01/01/1992 - "Longer exposure to antiparkinson drugs was associated with delayed onset of dyskinesia. " 01/01/2000 - "In logistic-regression analysis, the overall model attained significance in predicting functional impairment, and three predictor variables-abnormal movements, use of antiparkinsonian agents, and negative symptoms-attained independent significance. " 10/01/1989 - "Although the antimuscarinic antiparkinsonian agents are effective in reducing extrapyramidal symptoms, their use in conjunction with neuroleptic treatment of psychosis has been reported to antagonize the therapeutic effects of the neuroleptic; there are also several reports of the antimuscarinic antiparkinsonian agents variously causing psychotic syndromes, mood elevating and stimulant effects, stereotypy, dyskinesia, behavioral agitation, and drug dependence in both psychiatric and normal populations. " 06/14/1986 - "The problems of long term treatment with antiparkinson drugs are numerous, involving increased involuntary movements, painful dystonic cramps, decrease or loss of therapeutic benefit, wearing-off, episodes of akinesia (on-off) and long periods of "freezing". " 05/01/2006 - "Physicians have been concerned about forestalling the appearance of dyskinesias and motor fluctuations, whereas patients have incorrectly understood that L-dopa and possibly other antiparkinson drugs have a finite duration of usefulness, making it important to defer treatment for as long as possible. "
2.	Parkinson Disease (Parkinson's Disease) 03/01/2014 - "We examine the associations of adherence to antiparkinson drugs (APDs) with health care utilization and economic outcomes among patients with Parkinson's disease (PD). " 10/01/2013 - "Antiparkinson drugs (APDs) are the mainstay of managing Parkinson's disease (PD). " 08/01/2010 - "Antiparkinson drugs (APDs) are the mainstay in the management of Parkinson's disease (PD). " 12/01/2006 - "To analyze the dispensation of antiparkinsonian agents in Spain and to estimate the Parkinson's disease prevalence. " 10/01/2003 - "Patients in the late stages of Parkinson's disease may be significantly disabled for many years, often because of their increasing inability to tolerate therapeutic doses of antiparkinson drugs. "
3.	Dystonia (Limb Dystonia) 09/01/1987 - "Recent research suggests efficacy of prophylactic antiparkinson drugs in diminishing the incidence of acute dystonia in high-risk patients, although the use of lower neuroleptic doses also might lower the risk and cause fewer unwanted effects. " 10/01/1987 - "If confirmed, these data may allow treatment strategies that protect patients from dystonia while sparing patients not at risk unnecessary treatment with antiparkinson agents." 01/01/1988 - "Neuropharmacological studies performed in 12 patients suggest that off-period dystonia is genuinely induced by L-dopa and best relieved by antiparkinsonian agents."
4.	Catalepsy 11/01/2012 - "Synthesis of 1-(substituted aryl)-3-(thiazol-2-yl)urea derivatives was undertaken as our efforts to discover novel antiparkinsonian agents with improved pharmacological profile in haloperidol-induced catalepsy and oxidative stress in mice. " 07/01/1987 - "In rats receiving taurine in a dose of 450 micrograms, not influencing catalepsy, with low doses of anticholinergic antiparkinsonian agents (trihexyphenidyl and pridinol) strong anticataleptic effect was observed. " 01/01/1994 - "Amantadine (25, 50, 100 mg/kg), memantine (5, 10, 20 mg/kg) and MK-801 (0.05, 0.1, 0.2 mg/kg), all having NMDA channel blocking properties, were compared in three tests used for screening of antiparkinsonian agents in rats, namely: haloperidol-induced catalepsy, locomotor activity in monoamine depleted rats and rotation in rats with a unilateral substantia nigra lesion. " 11/01/1985 - "The influence of antidepressants: nomifensine, imipramine, amitriptyline and trazodone on the effect of antiparkinsonian agents: trihexyphenidil and L-DOPA + carbidopa mixture (sinemet) in the model of haloperidol catalepsy was investigated in rats. "
5.	Substance-Related Disorders (Drug Abuse) 02/01/2009 - "These patients have a very high prevalence of legal and illegal drug abuse, but the risk of abuse of anticholinergic antiparkinson drugs seemed small." 10/01/1989 - "Although the antimuscarinic antiparkinsonian agents are effective in reducing extrapyramidal symptoms, their use in conjunction with neuroleptic treatment of psychosis has been reported to antagonize the therapeutic effects of the neuroleptic; there are also several reports of the antimuscarinic antiparkinsonian agents variously causing psychotic syndromes, mood elevating and stimulant effects, stereotypy, dyskinesia, behavioral agitation, and drug dependence in both psychiatric and normal populations. "

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	Haloperidol (Haldol)
3.	Tiapride
4.	dironyl (terguride)
5.	Antidepressive Agents (Antidepressants)
6.	Benzodiazepines
7.	pramipexol (pramipexole)
8.	Soman
9.	Antipsychotic Agents (Antipsychotics)
10.	Anticonvulsants (Antiepileptic Drugs)

Related Therapies and Procedures

1.	Subcutaneous Injections
2.	Polypharmacy
3.	Perioperative Period
4.	Intravenous Infusions
5.	Home Nursing (Nursing, Home)